FDA rejects Alnylam's Onpattro label expansion after adcomm voted in favor - Endpoints News


10/9/2023

FDA rejects Alnylam's Onpattro label expansion after adcomm voted in favor  Endpoints NewsFDA rejects Alnylam's heart disease treatment over insufficient data  STATAlnylam abandons Onpattro expansion in US as FDA spurns rare heart disease bid  FiercePharmaFDA rejects Alnylam’s request to expand approval of one of its drugs to include heart patients  The Boston GlobeAlnylam Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis  Business WireView Full Coverage on Google News...

Original

Tags: announces | boston | complete | coverage | disease | drug | drugs | fda | full | google | heart | include | news | rare | response | treatment | u.s.



Let us know what you think!

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

Leave a Comment

Scroll back to top